Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The price of CorMedix Inc (NASDAQ: CRMD) closed at $11.19 in the last session, up 0.99% from day before closing price of $11.08. In other words, the price has increased by $0.99 from its previous closing price. On the day, 2.37 million shares were traded. CRMD stock price reached its highest trading level at $11.275 during the session, while it also had its lowest trading level at $10.9.
Ratios:
We take a closer look at CRMD’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.60 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 28.83. For the most recent quarter (mrq), Quick Ratio is recorded 7.52 and its Current Ratio is at 7.82. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On June 30, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $20.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 10 ’25 when Erin Mistry bought 13,543 shares for $10.98 per share.
Erin Mistry bought 13,908 shares of CRMD for $152,503 on Nov 06 ’25. On Oct 23 ’25, another insider, Kaplan Myron, who serves as the Director of the company, bought 25,000 shares for $11.02 each. As a result, the insider paid 275,500 and bolstered with 201,034 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRMD now has a Market Capitalization of 876725888 and an Enterprise Value of 645045760. As of this moment, CorMedix’s Price-to-Earnings (P/E) ratio for their current fiscal year is 14.99, and their Forward P/E ratio for the next fiscal year is 4.50. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.22 while its Price-to-Book (P/B) ratio in mrq is 3.78. Its current Enterprise Value per Revenue stands at 5.31 whereas that against EBITDA is 12.939.
Stock Price History:
The Beta on a monthly basis for CRMD is 1.31, which has changed by -0.023788571 over the last 52 weeks, in comparison to a change of 0.14151978 over the same period for the S&P500. Over the past 52 weeks, CRMD has reached a high of $17.43, while it has fallen to a 52-week low of $5.60. The 50-Day Moving Average of the stock is -2.59%, while the 200-Day Moving Average is calculated to be 0.17%.
Shares Statistics:
According to the various share statistics, CRMD traded on average about 3.24M shares per day over the past 3-months and 2514200 shares per day over the past 10 days. A total of 74.62M shares are outstanding, with a floating share count of 70.17M. Insiders hold about 10.44% of the company’s shares, while institutions hold 45.52% stake in the company. Shares short for CRMD as of 1761868800 were 16599216 with a Short Ratio of 5.00, compared to 1759190400 on 15564623. Therefore, it implies a Short% of Shares Outstanding of 16599216 and a Short% of Float of 21.39.
Earnings Estimates
The company has 7.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $0.82, with high estimates of $1.24 and low estimates of $0.59.
Analysts are recommending an EPS of between $2.82 and $1.52 for the fiscal current year, implying an average EPS of $2.08. EPS for the following year is $2.49, with 7.0 analysts recommending between $2.91 and $2.19.
Revenue Estimates
According to 7 analysts,. The current quarter’s revenue is expected to be $86.02M. It ranges from a high estimate of $125M to a low estimate of $65M. As of. The current estimate, CorMedix Inc’s year-ago sales were $11.46MFor the next quarter, 7 analysts are estimating revenue of $118.85M. There is a high estimate of $140M for the next quarter, whereas the lowest estimate is $97.5M.
A total of 7 analysts have provided revenue estimates for CRMD’s current fiscal year. The highest revenue estimate was $343.82M, while the lowest revenue estimate was $249M, resulting in an average revenue estimate of $283.66M. In the same quarter a year ago, actual revenue was $43.47MBased on 7 analysts’ estimates, the company’s revenue will be $410.87M in the next fiscal year. The high estimate is $487.03M and the low estimate is $304.1M.
